Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 4/2020

01-04-2020 | Lung Cancer | Original Article

Association of employment and company size with lung cancer screening participation among Japanese based on the socioeconomic conditions using the Comprehensive Survey of Living Conditions

Authors: Mitsuya Maeda, Ronald Filomeno, Yumi Kawata, Tomoyo Sato, Koutatsu Maruyama, Motoki Endo, Hiroo Wada, Ai Ikeda, Takeshi Tanigawa

Published in: International Journal of Clinical Oncology | Issue 4/2020

Login to get access

Abstract

Background

The proportion of non-regularly employed persons has increased in Japan, but few studies have examined the relationship between employment status and lung cancer screening (LCS) participation.

Methods

Authors analyzed data from the 2010 Comprehensive Survey of Living Conditions in Japan. The anonymous responses of 28,951 people aged 40–69 years old were analyzed. Authors defined nine employment status categories: unemployed, regularly employed in a large-, middle-, and small-scale company, non-regularly employed in a large-, middle-, and small-scale company, self-employed, and other. LCS participation in the past year was surveyed through a self-reported questionnaire. Sex-specific prevalence ratios (PRs) and 95% confidence intervals (CIs) for LCS participation for all employment status categories, using the regularly employed in a middle-scale company category as the reference, were calculated using multivariable Poisson regression analysis, after adjusting for potentially confounding factors.

Results

Multivariable-adjusted PRs (95% CI) for LCS participation for the regularly employed in a large-scale company were 1.33 (1.25–1.41) in men and 1.53 (1.38–1.71) in women. Multivariable-adjusted PRs (95% CI) for LCS participation for the non-regularly employed in a middle- and small-scale company compared with the regularly employed in a middle-scale company were 0.81 (0.72–0.92) and 0.62 (0.50–0.76) in men, and 0.89 (0.80–0.99) and 0.80 (0.71–0.91) in women, respectively.

Conclusion

Regularly employed in a large-scale company had significantly higher LCS participation, and non-regularly employed in a middle- or small-scale company showed significantly lower LCS participation than those who were regularly employed in a middle-scale company.
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386CrossRef
2.
Islami F, Torre LA, Jemal A (2015) Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res 4(4):327–338PubMedPubMedCentral
3.
4.
Tsukada H, Kurita Y, Yokoyama A et al (2001) An evaluation of screening for lung cancer in Niigata Prefecture, Japan: a population-based case–control study. Br J Cancer 85(9):1326CrossRef
5.
Hisamichi S (1996) Community screening programs of cancer and cardiovascular diseases in Japan. J Epidemiol 6(3sup):159–163CrossRef
6.
Sagawa M, Usuda K, Motono N et al (2012) Revised recommendations (2010 edition) on lung cancer screening in “lung cancer practice guidelines” of the Japanese lung cancer society. Jpn J Lung Cancer 52(6):938–942CrossRef
7.
Sano H, Goto R, Hamashima C (2014) What is the most effective strategy for improving the cancer screening rate in Japan? Asian Pac J Cancer Prev 15(15):2607–2612CrossRef
8.
Lo SH, Waller J, Vrinten C, Kobayashi L (2015) Social cognitive mediators of sociodemographic differences in colorectal cancer screening uptake. BioMed Res Int 2015:165074PubMedPubMedCentral
9.
Frederiksen BL, Jørgensen T, Brasso K et al (2010) Socioeconomic position and participation in colorectal cancer screening. Br J Cancer 103(10):1496–1501CrossRef
10.
11.
Parente F, Marino B, DeVecchi N et al (2009) Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer. Br J Surg 96(5):533–540CrossRef
12.
Wee LE, Koh GCH, Chin RT et al (2012) Socioeconomic factors affecting colorectal, breast and cervical cancer screening in an Asian urban low-income setting at baseline and post-intervention. Prev Med 55(1):61–67CrossRef
13.
Lee K, Lim HT, Hwang SS et al (2010) Socio-economic disparities in behavioural risk factors for cancer and use of cancer screening services in Korean adults aged 30 years and older: The Third Korean National Health and Nutrition Examination Survey, 2005 (KNHANES III). Public Health 124(12):698–704CrossRef
14.
Lin SJ (2008) Factors influencing the uptake of screening services for breast and cervical cancer in Taiwan. J R Soc Promot Health 128(6):327–334CrossRef
15.
Sambamoorthi U, McAlpine DD (2003) Racial, ethnic, socioeconomic, and access disparities in the use of preventive services among women. Prev Med 37(5):475–484CrossRef
16.
Taylor RJ, Mamoon HA, Morrell SL et al (2001) Cervical screening by socio-economic status in Australia. Aust N Z J Public Health 25(3):256–260CrossRef
17.
Fukuda Y, Nakamura K, Takano T et al (2007) Socioeconomic status and cancer screening in Japanese males: Large inequality in middle-aged and urban residents. Environ Health Prev Med 12(2):90–96CrossRef
18.
19.
Hamashima C, Yoshida K (2003) What is important for the introduction of cancer screening in the workplace? Asian Pac J Cancer Prev 4(1):39–44PubMed
20.
21.
Nishikitani M, Tsurugano S, Inoue M et al (2012) Effect of unequal employment status on workers’ health: results from a Japanese national survey. Soc Sci Med 75(3):439–451CrossRef
22.
23.
24.
25.
Seko R, Kawado M, Saito S et al (2019) Associations of occupation, employment type and company size with actions related to health examinations among Japanese employees. Ind Health 57(4):537–546CrossRef
26.
27.
Inoue M, Tsurugano S, Nishikitani M et al (2012) Full-time workers with precarious employment face lower protection for receiving annual health check-ups. Am J Ind Med 55(10):884–892CrossRef
28.
Shin JY, Lee DH (2012) Factors associated with the use of gastric cancer screening services in Korea: The Fourth Korea National Health and Nutrition Examination Survey 2008 (KNHANES IV). Asian Pac J Cancer Prev 13(8):3773–3779CrossRef
29.
Ali N, Lifford KJ, Carter B et al (2015) Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. BMJ Open 5(7):e008254CrossRef
30.
Tonge JE, Atack M, Crosbie PA et al (2019) “To know or not to know…?” Push and pull in ever smokers lung screening uptake decision-making intentions. Health Expect 22(2):162–172CrossRef
31.
Silvestri GA, Nietert PJ, Zoller J et al (2007) Attitudes towards screening for lung cancer among smokers and their non-smoking counterparts. Thorax 62(2):126–130CrossRef
32.
van Klaveren RJ, de Koning HJ, Mulshine J, et al (2002) Lung cancer screening by spiral CT. What is the optimal target population for screening trials? Lung Cancer 38(3): 243–252.
33.
Sackett DL (1979) Bias in analytic research. J Chronic Dis 32(1–2):51–63CrossRef
34.
Delgado-Rodriguez M, Llorca J (2004) Bias. J Epidemiol Commun Health 58(8):635–641CrossRef
35.
36.
37.
Metadata
Title
Association of employment and company size with lung cancer screening participation among Japanese based on the socioeconomic conditions using the Comprehensive Survey of Living Conditions
Authors
Mitsuya Maeda
Ronald Filomeno
Yumi Kawata
Tomoyo Sato
Koutatsu Maruyama
Motoki Endo
Hiroo Wada
Ai Ikeda
Takeshi Tanigawa
Publication date
01-04-2020
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 4/2020
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01594-9

Other articles of this Issue 4/2020

International Journal of Clinical Oncology 4/2020 Go to the issue

Original Article

Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma

Correction

Correction to: Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study

Original Article

Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study

Original Article

Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities

Original Article

LINC00163 inhibits the invasion and metastasis of gastric cancer cells as a ceRNA by sponging miR-183 to regulate the expression of AKAP12

Original Article

Research on the predicting power of the revised Tokuhashi system: how much time can surgery give to patients with short life expectancy?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits